Business
NurExone Biologic's U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization
TORONTO, Ontario and HAIFA, Israel and POMPANO BEACH, Florida, April 07, 2026 (GLOBE NEWSWIRE) --...
About this update from Nurexone Biologic Inc
[{"type":"text","content":"NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization\nTORONTO, Ontario and HAIFA, Israel and POMPANO BEACH, Florida, April 07, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) and BioXtek Inc. (“BioXtek”) today announced that Exo-Top Inc., NurExone’s wholly owned U.S. subsidiary, (“Exo-Top” and together, with BioXtek, the “Parties”) has entered into a non-binding letter of intent (the “LOI”) with BioXtek, a Florida-based company, to explore a strategic partnership in the field of regenerative therapies for exosome manufacturing and commercialization. The Parties intend to negotiate a strategic partnership to support U.S. Good Manufacturing Practice (“GMP”) manufacturing, clinical supply, and potential commercialization of bone marrow–derived mesenchymal stem cell (“MSC”) exosomes in the U.S. and international markets. The collaboration is expected to combine Exo-Top’s MSC Master Cell Bank (“MCB”) and exosome production expertise with BioXtek’s U.S. manufacturing infrastructure and commercialization capabilities to accelerate clinical and commercial exosome supply, and expand production capacity. In addition, the partnership is expected to address the growing demand for naïve exosomes across multiple therapeutic areas including the exosome-based regenerative aesthetics market which is experiencing rapid growth and is projected to surpass $1.6 billion by 2034⁽1⁾. “This collaboration aims to strengthen our manufacturing readiness, accelerate our clinical timelines, and create additional commercial opportunities for our exosome platform,” said Lior Shaltiel, Ph.D., Chief Executive Officer of NurExone. “BioXtek brings an operational U.S. GMP facility and established manufacturing capabilities, while we contribute our proprietary know-how and MCB, which serves as a standardized source for our MSC exosomes.” “NurExone has developed a highly compelling exosome platform and demonstrated strong consistency and quality in its production approach,” said Bruce Werber, M.D., C...